Editorial: Application of Cytometry in Primary Immunodeficiencies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F20%3A10410757" target="_blank" >RIV/00064203:_____/20:10410757 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/20:10410757

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F4You6TttM" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F4You6TttM</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fimmu.2020.00463" target="_blank" >10.3389/fimmu.2020.00463</a>

Result language

angličtina

Original language name

Editorial: Application of Cytometry in Primary Immunodeficiencies

Original language description

Since the first commercial flow cytometers became available in the 1970s, the field of flow cytometry (flow) has seen prodigious growth. Several scientific discoveries contributed to the development of this field, including the staining properties of fluorescein by Paul Ehrlich and a systematic sizing of microscopic particles by Coulter. In the late 1960s Bonner, Sweet, Hulett and Herzenberg at Stanford University designed and patented the first Fluorescence Activated Cell Sorter (FACS) instrument, and at the same time a German researcher, Wolfgang Göhde developed a fluorescence-based flow cytometer. Since then, flow has become an essential tool not only in research but also in diagnostic settings, where it can deliver results within a few hours. Hematopathologists routinely use flow to precisely define and classify hematological malignancies, as well as to evaluate and monitor outcomes of treatment, and detect minimal residual disease (MRD) after chemotherapy or immune reconstitution after hematopoietic cell transplantation (HCT). The ability to identify, quantitate and characterize immune cells has been a continuous source of new information on development, function, and alterations in the context of disease. This is particularly true in the field of inborn errors of immunity with 416 genetic defects described, 64 of which have been identified in the past 2 years (1). In these diseases, patients present with complex changes in their immune cells (both phenotypic and functional) and the versatile nature of multiparametric flow has allowed a thorough characterization. The flow-based immunological tests range from the relatively basic and easy to adopt (lymphocyte subset quantitation -T,B, and NK cells), to the more challenging, yet standardized tests with up to 10 markers, or exploratory panels with up to 23 fluorescent markers. Another common use of flow is the detection of specific protein (surface or intracellular) whose absence leads to immunodeficiency. Additionally, flow can beusedasaread-outforfunctionalresponsestoavarietyofsignalspermittingsinglecellevaluation. This Research Topic on Flow Cytometry for Primary Immunodeficiencies covers the spectrum of flow assays-immunophenotyping, protein detection and functional analysis, for diagnosis and monitoring of patients with these complex diseases. In the future, we are likely to see further advances in flow, in technology and instrumentation, but also in throughput and data analysis. Techniques that are currently confined to the research realm, such as mass cytometry or spectral cytometry, are likely to find their way to the diagnostic laboratory, with applications in practical clinical immunology. Further, there will also be improvements in reagents, specifically for human immunology, allowing higher degrees of standardization within and between laboratories. The next decade promises to be exciting and innovative for flow, especially for immune-mediated diseases.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NV18-03-00343" target="_blank" >NV18-03-00343: Immune monitoring and minimal residual disease detection in the context of targeted therapies in acute lymphoblastic leukemia</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů